Evidence map›Paper›PMID 40651600›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2025

Therapeutic nanoparticle safety in pregnancy: Bridging knowledge gaps with environmental insights and a translational roadmap.

Julia Felsenstein, Katherine M Nelson, Jasmine Shirazi, Jason P Gleghorn

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Protein Language Models are Accidental Taxonomists.bioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Julia FelsensteinDepartment of Biological Sciences, University of Delaware, Newark, DE, USA.
Katherine M NelsonDepartment of Biomedical Engineering, University of Delaware, Newark, DE, USA.
Jasmine ShiraziDepartment of Biomedical Engineering, University of Delaware, Newark, DE, USA.
Jason P GleghornDepartment of Biological Sciences, University of Delaware, Newark, DE, USA; Department of Biomedical Engineering, University of Delaware, Newark, DE, USA. Electronic address: gleghorn@udel.edu.

Funding

Subproject Title: Clinical Research Education, Mentoring and Career Development CoreU54GM104941 · NIGMS · UNIVERSITY OF DELAWARE · PI Gregory E Hicks · 2013 to 2026
$60.5M
Chemistry-Biology Interface Predoctoral Training Grant 2024-2029T32GM133395 · NIGMS · UNIVERSITY OF DELAWARE · PI Catherine Leimkuhler Grimes · 2019 to 2026
$3.7M
The impact of the physical microenvironment on trophoblast functionF31HD105398 · NICHD · UNIVERSITY OF DELAWARE · PI NELSON, KATHERINE · 2021 to 2023
$122k
NICHD NIH HHS F31 HD105398NIGMS NIH HHS T32 GM133395NIGMS NIH HHS U54 GM104941
6 · The paper itself

Abstract

The use of nanoparticles (NPs) for therapeutic applications is an expanding field that has more recently begun to focus on pregnancy-related disorders. As the range of medical applications and the types of particles considered for therapeutic use expands, a detailed understanding of the possible risks of exposure during pregnancy is imperative. This review will examine how NP exposure can directly and indirectly affect placental growth and fetal development, as well as its effects on postnatal growth, and summarize the current research on NPs as drug delivery vehicles for treating pregnancy-related disorders. It will also examine how specific particle compositions and surface functionalities may improve particle biocompatibility and, thus, outcomes for the pregnant person and fetus. By assessing the safety of exposure for pregnant individuals and their developing fetuses, and providing insight into how toxicity studies can be made more comprehensive and follow ethical and regulatory guidelines, this review will offer researchers promising approaches for advancing nanotechnology in the maternal-fetal health space while prioritizing patient safety.

Indexed as

NanoparticlesAnimalsDrug Delivery SystemsFemaleFetal DevelopmentHumansPregnancyDrug deliveryMaternal-fetal healthNanoparticlesPregnancyToxicity

Identifiers

PMID40651600
PMCPMC12379451

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.